Combination therapy before surgery for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs and chemotherapy given before surgery for a type of rectal cancer that has a specific genetic marker (MSI-H/dMMR). The goal is to shrink the tumor and improve the chances of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of rectal cancer called adenocarcinoma that is locally advanced (has not spread to distant organs) and has a specific genetic feature (MSI-H or dMMR).
- You cannot have had any previous cancer treatment, such as surgery, chemotherapy, or radiation.
- You must be in generally good health, with adequate organ function (kidneys, liver, blood counts, etc.).
- You must not have other active cancers or serious medical conditions that could interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial tests a combination of drugs given before surgery to shrink rectal cancer tumors and improve the chances of successful surgery. The drugs include an immunotherapy called serplulimab, chemotherapy (XELOX), and a targeted therapy called bevacizumab. This approach may help reduce the risk of the cancer coming back.
This trial tests a combination of three drugs (serplulimab, CAPOX, and bevacizumab) given before surgery to shrink locally advanced rectal cancer. The goal is to make the tumor easier to remove and potentially improve outcomes.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
Hear when a new MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.